December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Photodynamic Therapy with Verteporfin: Comparison of Clinical Outcomes with TAP Study Group
Author Affiliations & Notes
  • SJ Sramek
    Ophthalmology Davis Duehr Dean Madison WI
  • JE Kim
    Ophthalmology Medical College of Wisconsin Milwaukee WI
  • CE Hoitink
    Ophthalmology Medical College of Wisconsin Milwaukee WI
  • MD Wolf
    Ophthalmology Davis Duehr Dean Madison WI
  • DP Han
    Ophthalmology Medical College of Wisconsin Milwaukee WI
  • TB Connor
    Ophthalmology Medical College of Wisconsin Milwaukee WI
  • WJ Wirostko
    Ophthalmology Medical College of Wisconsin Milwaukee WI
  • Footnotes
    Commercial Relationships   S.J. Sramek, None; J.E. Kim, None; C.E. Hoitink, None; M.D. Wolf, None; D.P. Han, None; T.B. Connor, None; W.J. Wirostko, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 577. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SJ Sramek, JE Kim, CE Hoitink, MD Wolf, DP Han, TB Connor, WJ Wirostko; Photodynamic Therapy with Verteporfin: Comparison of Clinical Outcomes with TAP Study Group . Invest. Ophthalmol. Vis. Sci. 2002;43(13):577.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate our treatment endpoints and outcomes withPhotodynamic Therapy (PDT) with verteporfin and compare to theresults of the Treatment of Age-Related Macular Degenerationwith PDT (TAP) Study.Methods:Chart review of consecutive patientswho underwent PDT for predominantly classic subfoveal CNVM secondaryto age-related macular degeneration who had at least six monthsof follow-up or in whom further treatment was not recommended.Patients with pretreatment vision worse than 20/200 were notexcluded (33/132, 25%).Results:Treatment was stopped in 95of 132 eyes (71%) after an average of two treatments (range1-4, average follow-up 39 weeks). In the remaining 27 eyes,treatment is ongoing (3.2 treatments, range 2-5, average follow-up37 weeks). The distribution of patients who were noted to havea three-line change in visual acuity as well as visual acuitydistribution at the last exam were similar to the TAP results.Fluorescein angiography three months after the first PDT treatmentshowed CNVM size and leakage increased in 53% and 40%, respectively.Conclusion: In a majority of patients, fewer treatments werenecessary to achieve clinical stability compared to the averagenumber of treatments in the TAP protocol (2 vs. 5.6). Visualresults were comparable considering differences in pretreatmentvision, but may also change with longer follow-up of our series.Increased CNVM size and leakage in nearly half of the treatedeyes at three months follow-up suggests earlier retreatmentmay be beneficial. Three Line Vision Change  

Acuity Distribution atLast Exam 

Keywords: 308 age-related macular degeneration • 516 photodynamic therapy • 454 laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×